A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT

NCT03190733 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

192

Enrollment

OTHER

Sponsor class

Conditions

Chronic Graft-versus-host-disease
Leukemia Relapse

Interventions

DRUG: ATG

Sponsor

Zhujiang Hospital

Collaborators

[object Object]
[object Object]
[object Object]